SDGR (Schrodinger Inc.) stock: $29.02, $2.17B market cap, $413.7M cash, $1.76B EV, $2.44B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
SGR-1505
Phase 1 · Active Modality: small molecule (MALT1 inhibitor)
Target MALT1
Partnerships Company exploring strategic partnerships to advance development beyond the ongoing Phase 1 trials. FDA orphan drug designations for mantle cell lymphoma (Aug 2023) and Waldenström macroglobulinemia (Oct 2025); fast track designation for WM patients who failed ≥2 lines including a BTK inhibitor (Jun 2025).
Indications- Relapsed or refractory B-cell malignancies (incl. mantle cell lymphoma, Waldenström macroglobulinemia) (Phase 1)
Status note Novel oral MALT1 inhibitor. Phase 1 dose-escalation trial in patients with relapsed or refractory B-cell malignancies (up to 98 patients, U.S./Europe) ongoing; a Phase 1 healthy-volunteer trial (73 subjects) completed.
SGR-3515
Phase 1 · Active Modality: small molecule (Wee1/Myt1 inhibitor)
Target Wee1/Myt1
Partnerships Company exploring strategic partnerships to advance development beyond the ongoing Phase 1 trial.
Indications- Advanced solid tumors (Phase 1)
Status note Novel Wee1/Myt1 inhibitor for solid tumors, selected via the company's computational platform. Phase 1 dose-escalation trial in patients with advanced solid tumors ongoing.
BMS collaboration programs
Stage not disclosed · Active Modality: small molecule (discovery collaboration)
Partnerships Exclusive worldwide collaboration and license with Bristol-Myers Squibb (Nov 2020, amended Dec 2022); BMS eligible programs reduced to one remaining neurology target; up to $482M total milestones ($257M research/development/regulatory + $225M commercial), mid-single to low-double digit royalties.
Indications- Neurology (one target remaining) (Stage not disclosed)
Status note Drug discovery collaboration for small molecule compounds in oncology, neurology and immunology; as of Jun 30, 2026 only one neurology target remains active. Phase not disclosed in the excerpts.
Novartis collaboration programs
Stage not disclosed · Active Modality: small molecule (discovery collaboration)
Partnerships Research collaboration and license with Novartis Pharma AG (Nov 2024) plus expanded three-year software agreement; $150M upfront; up to $2.272B total milestones ($892M discovery/development + $1.38B commercial), mid-single to low-double digit royalties; Novartis solely responsible for development/manufacturing/commercialization of identified candidates.
Indications- Multiple therapeutic areas (Stage not disclosed)
Status note Discovery, research and preclinical development collaboration for small molecule compounds across specified therapeutic areas. Phase not disclosed in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.